Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study
| Autor: | Manas Ranjan Mishra, Siddhartha Goutam, Jyotirmoyee Jena, Ratikanta Tripathy, Dayanidhi Meher, Vidhya Sreekumar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Triglyceride Physiology business.industry Saroglitazar nutritional and metabolic diseases medicine.disease Gastroenterology chemistry.chemical_compound Postprandial chemistry Internal medicine Diabetes mellitus medicine General Pharmacology Toxicology and Pharmaceutics business Pioglitazone Dyslipidemia Glycemic medicine.drug Lipoprotein |
| Zdroj: | National Journal of Physiology, Pharmacy and Pharmacology. :1 |
| ISSN: | 2320-4672 |
| Popis: | Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit. The introduction of dual peroxisome proliferator-activated receptors agonist has provided a new insight into the management of both diabetes and dyslipidemia. Aim and Objective: Hence, this study aimed to compare the effect of saroglitazar and pioglitazone on the lipid parameters and glycemic profile in patients of diabetes mellitus with dyslipidemia. Materials and Methods: Adult patients with diabetic mellitus with dyslipidemia fulfilling the inclusion criteria were included in the study. One group received saroglitazar (4 mg/day) and the other group received pioglitazone (15 mg/day). Lipid parameters; triglyceride (TG), low-density lipoprotein, high-density lipoprotein (HDL), and serum cholesterol levels and glycemic parameters; fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycosylated hemoglobin (HbA1C) were measured at baseline and month 3, 6, and 12. Results: Significant improvement seen in TG and HDL level at month 12 from baseline in both the treatment groups but saroglitazar was more effective than pioglitazone (P < 0.05). FPG, PPPG, and HbA1C were also reduced significantly from the baseline at the end of the study period (P < 0.05). Both the drugs were not associated with any sever adverse drug reactions. Conclusion: The current study showed that saroglitazar was more effective than pioglitazone in controlling lipid and glycemic parameters in diabetic patients with dyslipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|